• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伴有或不伴有勃起功能障碍的良性前列腺增生症的治疗管理选择：聚焦于他达拉非及患者考量因素

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.

作者信息

Alsaikhan Bader, Alrabeeah Khalid, Carrier Serge

机构信息

McGill University Health Centre, Montreal, Quebec, QC, Canada.

出版信息

Int J Gen Med. 2014 Jun 12;7:271-6. doi: 10.2147/IJGM.S40216. eCollection 2014.

DOI:10.2147/IJGM.S40216
PMID:24959092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4061160/
Abstract

Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads to decreased relaxation of the bladder wall and prostate and worsening LUTS. In this review article, we will focus on the potential use and clinical significance of phosphodiesterase-5 inhibitors in the treatment of LUTS secondary to benign prostate hyperplasia.

摘要

下尿路症状（LUTS）和勃起功能障碍会随着年龄的增长而增加。多项研究已证实这两种疾病之间存在真正的关联。基础研究表明，随着年龄的增长，一氧化氮/环磷酸鸟苷途径显著减少，导致膀胱壁和前列腺松弛功能下降，进而使下尿路症状恶化。在这篇综述文章中，我们将重点关注磷酸二酯酶-5抑制剂在治疗良性前列腺增生继发的下尿路症状方面的潜在用途和临床意义。

相似文献

1
Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.伴有或不伴有勃起功能障碍的良性前列腺增生症的治疗管理选择：聚焦于他达拉非及患者考量因素
Int J Gen Med. 2014 Jun 12;7:271-6. doi: 10.2147/IJGM.S40216. eCollection 2014.
2
Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.用于治疗良性前列腺增生所致下尿路症状的5型磷酸二酯酶抑制剂的最新进展
Rev Urol. 2012;14(3-4):79-86.
3
Tadalafil for the treatment of benign prostatic hyperplasia.他达拉非治疗良性前列腺增生。
Expert Opin Pharmacother. 2019 Jun;20(8):929-937. doi: 10.1080/14656566.2019.1589452. Epub 2019 Mar 22.
4
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].[磷酸二酯酶-5抑制剂治疗良性前列腺增生合并勃起功能障碍患者下尿路症状的疗效]
Urologiia. 2019 Sep(4):130-134.
5
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.磷酸二酯酶 5 抑制剂治疗良性前列腺增生症下尿路症状的最新证据。
Eur Urol. 2016 Jul;70(1):124-133. doi: 10.1016/j.eururo.2015.12.048. Epub 2016 Jan 22.
6
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.他达拉非对下尿路症状的直接作用与通过改善勃起功能障碍症状介导的间接作用：4 项安慰剂对照临床研究的综合数据分析。
J Urol. 2014 Feb;191(2):405-11. doi: 10.1016/j.juro.2013.09.057. Epub 2013 Oct 1.
7
Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms.5型磷酸二酯酶抑制剂与下尿路症状中的勃起功能障碍
Low Urin Tract Symptoms. 2012 Mar;4 Suppl 1:75-80. doi: 10.1111/j.1757-5672.2011.00121.x.
8
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.下尿路症状/良性前列腺增生与血管功能：一氧化氮-5型磷酸二酯酶-环磷酸鸟苷途径的作用
Int J Urol. 2017 Jun;24(6):412-424. doi: 10.1111/iju.13336. Epub 2017 Mar 22.
9
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.他达拉非对良性前列腺增生继发的下尿路症状及对同时患有这两种病症的性活跃男性勃起功能障碍的影响：来自四项随机、安慰剂对照他达拉非临床研究的汇总数据分析
J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19.
10
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.每日一次坦索罗辛 5 毫克治疗伴或不伴勃起功能障碍的下尿路症状提示良性前列腺增生症男性的疗效：自然观察性 TadaLutsEd 研究结果。
J Sex Med. 2014 Feb;11(2):498-505. doi: 10.1111/jsm.12386. Epub 2013 Nov 13.

引用本文的文献

1
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.用于治疗与良性前列腺增生相关的下尿路症状的磷酸二酯酶抑制剂。
Cochrane Database Syst Rev. 2018 Nov 16;11(11):CD010060. doi: 10.1002/14651858.CD010060.pub2.
2
The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review.磷酸二酯酶-5抑制剂在前列腺炎症中的作用：综述
J Inflamm (Lond). 2015 Sep 15;12:54. doi: 10.1186/s12950-015-0099-7. eCollection 2015.

本文引用的文献

1
A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.一项比较随机前瞻性研究，旨在评估坦索罗辛和他达拉非联合与坦索罗辛或他达拉非单药治疗良性前列腺增生所致下尿路症状的疗效和安全性。
J Sex Med. 2014 Jan;11(1):187-96. doi: 10.1111/jsm.12357. Epub 2013 Oct 25.
2
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.每日一次他达拉非联合非那雄胺治疗良性前列腺增生所致下尿路症状和前列腺增生的 6 个月疗效和安全性。
J Urol. 2014 Mar;191(3):727-33. doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2.
3
Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis.他达拉非单药治疗良性前列腺增生继发下尿路症状的疗效和安全性：一项荟萃分析。
Urol Int. 2013;91(1):10-8. doi: 10.1159/000351405. Epub 2013 Jun 25.
4
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.他达拉非对良性前列腺增生继发的下尿路症状及对同时患有这两种病症的性活跃男性勃起功能障碍的影响：来自四项随机、安慰剂对照他达拉非临床研究的汇总数据分析
J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19.
5
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity.脊髓中存在磷酸二酯酶 5 及其与膀胱流出道梗阻相关的膀胱过度活动症的关系。
J Urol. 2013 Oct;190(4):1430-5. doi: 10.1016/j.juro.2013.03.112. Epub 2013 Mar 29.
6
Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.他达拉非：用于治疗有或无勃起功能障碍的良性前列腺增生的症状和体征。
Drugs Aging. 2012 Sep;29(9):771-81. doi: 10.1007/s40266-012-0010-7.
7
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.一项关于单独使用磷酸二酯酶 5 抑制剂或与α受体阻滞剂联合治疗良性前列腺增生所致下尿路症状的系统评价和荟萃分析。
Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25.
8
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.每日一次他达拉非治疗伴良性前列腺增生症状和体征的男性患者的血液动力学效应：多中心、随机、双盲、安慰剂对照试验结果。
Urology. 2012 Apr;79(4):875-82. doi: 10.1016/j.urology.2011.11.040. Epub 2012 Feb 14.
9
Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.下尿路中包括一氧化氮和磷酸二酯酶相关靶点在内的环核苷酸代谢
Handb Exp Pharmacol. 2011(202):527-42. doi: 10.1007/978-3-642-16499-6_23.
10
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.他达拉非治疗良性前列腺增生症继发下尿路症状：病理生理学和作用机制。
Neurourol Urodyn. 2011 Mar;30(3):292-301. doi: 10.1002/nau.20999. Epub 2011 Jan 31.